Myriad Genetics: In the Eye of a Policy Storm
E. Richard Gold
McGill University - Faculty of Law
affiliation not provided to SSRN
September 9, 2008
From the late 1980s, a storm surrounding the wisdom, ethics and economics of human gene patents has been brewing. The various winds of concern in this storm touched on the impact of gene patents on basic and clinical research, on health care delivery, and on the ability of public health care systems to provide equal access when faced with costly patented genetic diagnostic tests. Myriad Genetics, Inc. along with its subsidiary, Myriad Genetic Laboratories, Inc., a small Utah-based biotechnology company, found itself unwittingly in the eye of this storm after a series of decisions it made regarding the commercialization of a hereditary breast cancer diagnostic test. This case study examine the background to Myriad's decisions, the context in which these decisions were made and the policy, research and business response to them.
Number of Pages in PDF File: 59
Keywords: Myriad Genetics, genes, patents, ethics, business models, public health care, clinicial genetics, Europe, Canada, Australia, Japanworking papers series
Date posted: September 12, 2008
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo3 in 0.485 seconds